

Pfizer R&D Update

Mikael Dolsten, M.D., Ph.D.
President, Worldwide R&D
EVP, Pfizer Inc.

February 25, 2014



Forward-Looking Statements and Non-GAAP Financial Information

- Our discussions during this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer's 2012 Annual Report on Form 10-K/A and in our reports on Form 10-Q and Form 8-K.
- Also, the discussions during this meeting will include certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles. Reconciliations of those non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measures can be found in Pfizer's Current Report on Form 8-K dated January 28, 2014.
- These reports are available on our website at www.pfizer.com in the "Investors – SEC Filings" section.

R&D Turnaround Delivering Increased Productivity

Increased focus, rigor and discipline in R&D

Investments in pipeline, capabilities, new science and talent base

Relocation to key biomedical hubs complete

Strengthened technical platforms

Biologic, small molecule and vaccine design, Precision Medicine

Created new collaboration models to complement internal efforts

CTI, Innovative Biotech/Pharma/VC/Foundation partnerships

Reaching New Patients/Geographies with Recent Launches

Recent Launches



Prevention of
pneumococcal disease in
children & adults



Treatment of moderate
to severe RA



Stroke prevention in
A-Fib
VTE prevention ortho
surgery (EU only)



Treatment of ALK+
metastatic NSCLC



Menopausal symptoms;
osteoporosis prevention

Expansion Opportunities

- Pneumococcal disease prevention in adults


- Phase 3 in Psoriasis, Ulcerative Colitis, Psoriatic Arthritis
- Phase 2 in Crohn's, Ankylosing Spondylitis, Psoriasis (topical), Atopic Dermatitis

- In registration: VTE Treatment (US/EU)
- In registration: VTE Prevention (EU)

- Global indications for 1st-line ALK+ advanced non-small cell lung cancer

- EU action on submission

Innovative Next Wave Across Key Therapeutic Areas




Oncology

Key Phase 3 Programs

- Palbociclib: Breast Cancer
- *Trastuzumab**: Breast Cancer

Key Earlier Programs

- Inlyta, ALK1: Liver Cancer
- SMO: Blood Cancer
- ALK/ROS 2nd Gen: NSCLC
- 41BB & ADC MABs



Vaccine Research

- Meningococcal B Vaccine

- *Staph aureus* Vaccine
- *C. difficile* Vaccine



CV and Metabolic

- Bococizumab: Hyperlipidemia
- Ertugliflozin: Type 2 Diabetes (with Merck)

- PDE5 & CCR 2/5: CKD
- pGKA, GlucR: Diabetes



Immunology & Inflammation

- IL-6: Lupus, Crohn's
- MadCAM: IBD
- *Infliximab**, *Adalimumab**



Neuroscience & Pain

- ALO-02, Remoxy, Tanezumab**: Pain

- PDE10: Schizophrenia, HD
- Urat1/XO: Gout



Rare Disease

- Tafamadis: TTR-Cardiomyopathy

- Rivipansel: Sickle Cell
- RK35: Muscular Dystrophy



**Biosimilars move directly from Phase 1 to Phase 3*

***On clinical hold*

Q&A

